200 related articles for article (PubMed ID: 35279805)
1. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
Elewski BE; Blauvelt A; Gallo G; Wolf E; McKean-Matthews M; Burge R; Merola JF; Gottlieb AB; Guenther LC
Dermatol Ther (Heidelb); 2022 Apr; 12(4):911-920. PubMed ID: 35279805
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
Kirkham BW; Egeberg A; Behrens F; Pinter A; Merola JF; Holzkämper T; Gallo G; Ng KJ; Bolce R; Schuster C; Nash P; Puig L
Rheumatol Ther; 2023 Oct; 10(5):1127-1146. PubMed ID: 37400681
[TBL] [Abstract][Full Text] [Related]
3. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
4. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
[TBL] [Abstract][Full Text] [Related]
5. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
[TBL] [Abstract][Full Text] [Related]
6. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
Wasel N; Thaçi D; French LE; Conrad C; Dutronc Y; Gallo G; Berggren L; Lacour JP
Dermatol Ther (Heidelb); 2020 Aug; 10(4):663-670. PubMed ID: 32415575
[TBL] [Abstract][Full Text] [Related]
7. Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Gooderham M; Vender R; Crowley J; Hong HC; Feely M; Garrelts A; See K; Konicek B; Green L
Dermatol Ther (Heidelb); 2024 Feb; 14(2):441-451. PubMed ID: 38332436
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.
Reich K; Kristensen LE; Smith SD; Rich P; Sapin C; Leage SL; McKenzie R; Schuster C; Riedl E; Gooderham M
Dermatol Pract Concept; 2022 May; 12(2):e2022104. PubMed ID: 35646453
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H.
Kristensen LE; Okada M; Tillett W; Leage SL; El Baou C; Sapin C; Bradley AJ; Meszaros G; Dutz JP; de Vlam K
Rheumatol Ther; 2022 Feb; 9(1):109-125. PubMed ID: 34709605
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
[TBL] [Abstract][Full Text] [Related]
11. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
Rich P; Goldblum O; Disch D; Lin CY; Merola JF; Elewski B
J Drugs Dermatol; 2020 Aug; 19(8):741-746. PubMed ID: 32845588
[TBL] [Abstract][Full Text] [Related]
12. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
[TBL] [Abstract][Full Text] [Related]
13. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.
McGonagle D; Kavanaugh A; McInnes IB; Kristensen LE; Merola JF; Strober B; Bolce R; Lisse J; Pustizzi J; Sapin C; Ritchlin C
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38341669
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
Armstrong AW; Jaleel T; Merola JF; Gottlieb AB; Khattri S; Helt CC; Malatestinic WN; Ross SE; Ngantcha ME; de Vlam K
Dermatol Ther (Heidelb); 2024 May; ():. PubMed ID: 38814433
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
[TBL] [Abstract][Full Text] [Related]
16. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
Egeberg A; Hawkes JE; Somani N; Burge R; See K; Gallo G; McKean-Matthews M; Gooderham M; Han G; Armstrong A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):1007-1018. PubMed ID: 38647975
[TBL] [Abstract][Full Text] [Related]
17. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
18. Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis.
Husein-ElAhmed H; Husein-ElAhmed S
Clin Exp Dermatol; 2023 Jul; 48(8):895-902. PubMed ID: 37052062
[TBL] [Abstract][Full Text] [Related]
19. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]